Ripertamab
Based on 1 Customer Validation
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 2249927-04-4
- Molecular Weight:144.56 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
CD20/MS4A1
Ripertamab specifically binds to the CD20 antigen on the surface of B cells, and effectively eliminates CD20-positive B cells through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and direct growth inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Ripertamab. The EC50 for this effect is 4.506 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ripertamab (HY-P99952). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2249927-04-4
-
Appearance Liquid
-
Molecular Weight 144.56 kDa
-
Color Colorless to light yellow
-
SMILES
[Ripertamab]
-
Synonyms
SCT400
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Crescioli S, et al. Antibodies to watch in 2025. MAbs. 2025;17(1):2443538. [Content Brief]
[2]. Wang X, et al. Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study. Front Immunol. 2025;16:1540694. Published 2025 Mar 26. [Content Brief]
[3]. Li X, et al. The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study. Sci Rep. 2025;15(1):20567. Published 2025 Jul 1. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Ripertamab
- 2249927-04-4
- SCT400
- SCT 400
- SCT-400
- CD20
- CD20 antigen
- B-cell non-Hodgkin lymphoma
- regulatory T-cell
- antibody-dependent cell-mediated cytotoxicity
- complement-dependent cytotoxicity
- idiopathic membranous nephropathy
- CD20-positive B cells
- transmembrane CD20
- B-cell surfaces
- primary membranous nephropathy
- Inhibitor
- inhibitor
- inhibit